14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Endothelial cell nitric oxide synthase 3 (NOS3; eNOS)

Genitourinary disease INDICATION: Genitourinary Patient sample and mouse studies suggest promoting NOS3 activity with Viagra sildenafil could help prevent preeclampsia. In patient placental tissue samples or vascular endothelium from a mouse model of preeclampsia, markers of NOS3...
08:00 , Feb 25, 2016 |  BC Innovations  |  Product R&D

Ironwood's brainy idea

Selina Koch, Staff Writer  Ironwood Pharmaceuticals Inc. is pushing the scope of what its soluble guanylate cyclase (sGC) platform can do, with a new preclinical program to make brain-penetrating compounds that could move the company beyond...
08:00 , Nov 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Pneumococcus; pneumonia Endothelial cell nitric oxide synthase 3 (NOS3; eNOS) Mouse studies suggest agonizing NOS3 could...
07:00 , May 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury Neuron-derived neurotrophic factor (NDNF); endothelial cell nitric oxide synthase 3 (NOS3; eNOS); protein kinase B...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertrophy Endothelial cell nitric oxide synthase 3 (NOS3; eNOS); regulator of G-protein signaling 4 (RGS4) In...
07:00 , Jun 28, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neuroinflammation Endothelial cell nitric oxide synthase 3 (NOS3; eNOS); VEGF-A Mouse studies...
07:00 , Jun 3, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Cardiovascular disease Hypertension; atherosclerosis Nitric oxide (NO); endothelial cell nitric oxide synthase 3 (NOS3; eNOS) In vitro studies suggest that analogs of the natural product xyloketal B could help treat hypertension and...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

Ocera preclinical data

In cirrhotic rats, OCR-002 significantly reduced levels of arterial ammonia, edema, inflammatory cytokines and endothelial cell nitric oxide synthase 3 ( NOS3; eNOS) activity in the brain and liver compared with control rats treated...
07:00 , Jun 11, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease ...